Compare Carvana Co (CVNA) vs 10X Genomics Inc (TXG) Price & Performance

Carvana (CVNA) trades at $63.21, up 0.72% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 revenue up 52% and net income of $1.41 billion in 2025. Analyst sentiment is divided, with a consensus price target of $84.07, but technical indicators suggest near-term resistance at $64.

The outlook for CVNA hinges on sustained revenue growth and margin expansion, supported by operational improvements and capacity expansions. Key risks include high debt levels, competitive pressures, and sensitivity to interest rates. Upside potential exists if the company continues to exceed earnings expectations and expand its market share in the online used car sector.

TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.

The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.